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Molecular Predictors of Sensitivity to the MET Inhibitor
PHA665752 in Lung Carcinoma Cells
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Hiroyuki Aburatani, MD, PhD,‡ Masashi Fukayama, MD, PhD,† and Toshiro Niki, MD, PhD*
Background: No comprehensive data are available on the molecu-
lar predictors of sensitivity to MET inhibitor in lung carcinomas.
Methods: We examined the efficacy of the MET inhibitor
PHA665752 in 41 cell lines of non-small lung carcinoma to deter-
mine whether sensitivity to the MET inhibitor is correlated with the
(1) genetic statuses of MET, epidermal growth factor receptor
(EGFR), human epidermal growth factor receptor 2, and KRAS, (2)
MET phosphorylation and its downstream signaling pathways, or (3)
epithelial-mesenchymal transition.
Results: Of the 41 cells, 8 were highly or intermediately sensitive to
PHA665752, and the remainder were PHA665752 resistant. The
sensitive cells (n  8) included not only 4 of 4 MET-amplified cell
lines but also 2 of 11 KRAS-mutated cell lines and 1 of 6 EGFR-
mutated cell lines. Unlike the MET-amplified cell lines, both the
MET-mutated cell lines were PHA665752 resistant. High phospho-
MET was not restricted to the four MET-amplified cell lines. To the
contrary, it was also found in 9 of 37 MET-nonamplified cell lines,
including 3 of 6 EGFR-mutated cell lines and 4 of 11 KRAS-
mutated cell lines. High phospho-MET was correlated with
PHA665752 sensitivity in the entire panel of cell lines, especially in
the KRAS-mutated cells. The AKT and ERK pathways in the high
phospho-MET cell lines were dependent on MET activation in
MET-amplified and KRAS-mutated cells but not in EGFR-mutated
and human epidermal growth factor receptor 2-amplified cells.
Conclusions: MET amplification is an excellent predictor of
PHA665752 sensitivity but not the sole predictor. High phospho-
MET and dependence of the AKT and ERK pathways on MET
activation may predict sensitivity to PHA665752, especially in
KRAS-mutated cell lines.
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Lung cancer is the leading cause of cancer mortality indeveloped countries. Molecularly targeted therapy is a
new therapeutic modality now under intense investigation.1
The epidermal growth factor receptor (EGFR) inhibitors
gefitinib and erlotinib have already shown promising results
for patients with lung adenocarcinomas.2 Molecular analyses
have demonstrated that EGFR-mutated tumors are commonly
sensitive to these EGFR inhibitors, whereas KRAS-mutated
tumors are most often resistant.3
MET is another receptor-type tyrosine kinase overex-
pressed and activated in a subset of lung adenocarcinoma tissues
and cell lines.4–6 Earlier studies have reported that a small
molecule MET inhibitor, PHA665752, inhibits the growth of
various cancer cell lines,7–10 and that MET amplification may be
useful for identifying cell lines sensitive to theMET inhibitor.8,10
Yet, the number of lung carcinoma cell lines tested in these
previous studies has been rather limited. In an examination of 40
human cancer cell lines by Smolen et al.,8 MET amplification
was harbored in 1 of 4 gastric cancer cell lines versus 0 of 12
lung cancer cell lines. In the study by Lutterbach et al.,10 two
MET-amplified lung cancer cell lines with high MET and high
phospho-MET expressions were compared with seven non-MET–
amplified lung cancer cell lines with low MET and low phospho-
MET expressions. According to their results, the former were
sensitive to MET inhibitor whereas the latter were resistant to it.
Although these results are clear, the nine cell lines analyzedmay not
fully represent the diversity of human lung cancer.
In this study, we performed a comprehensive analysis of a
large panel of lung carcinoma cell lines and sought to identify
molecular determinants of sensitivities to the MET inhibitor.
Specifically, we asked whether sensitivities to the MET inhibitor
are correlated with (1) the genetic statuses of MET, EGFR,
human epidermal growth factor receptor 2 (HER2), and KRAS;
(2) the phosphorylation of MET and its downstream signaling
pathways; or (3) epithelial-mesenchymal transition (EMT).
MATERIALS AND METHODS
Cell Lines and Medium
We used 41 non-small lung cancer cell lines. The sources
and histologic types of these cell lines are detailed in Figure 1.
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All cell lines were maintained in RPMI 1640 supplemented with
10% fetal calf serum, glutamine, and antibiotics in a humidified
atmosphere with 5% CO2 and 95% air.
Antibodies
The sources of the antibodies used in this study are
provided in Table 1.
DNA Sequencing
The DNA was extracted from cell lines by standard
procedures. The polymerase chain reaction (PCR) primers
and conditions for amplifying and sequencing exon 18
through exon 21 of the EGFR gene are described in the
previous literature.12 The mutation resulting in deletion of
exon 14 of MET was screened by amplifying cDNA
encompassing exon 14 of MET and examining the PCR
product size on gel electrophoresis. The PCR primers and
the conditions for mutational analysis of KRAS (codons
12, 13, and 61), MET (exons 2 and 3 encoding Sema
domain), and HER2 (exons 19 and 20) are available upon
request. The PCR products were sent to Macrogen Inc.
(http://www.macrogen.com/eng/macrogen/macrogen_main.jsp)
for sequencing.
Gene Expression Profile and Single Nucleotide
Polymorphism Array Analysis
A comprehensive gene expression analysis was per-
formed using an oligonucleotide microarray (GeneChip Hu-
man Genome U133A, Affymetrix, Santa Clara, CA) as de-
scribed previously.13 Single nucleotide polymorphism array
(Affymetrix human mapping 50K XbaI array) analysis was
FIGURE 1. Sensitivity of 41 non-small cell lung cancer cell lines to PHA665752 and their genetic statuses. Left panel shows
cell line names, histologies, sources, sensitivities, and the values of IC50. Middle panel shows the viability of cells with each
PHA665752 concentration in a different color. Right panel shows the genetic statuses of 41 cell lines. Details are shown at the
bottom of the figure. L27 was described in a previous study.11
TABLE 1. Antibodies Used in Western Blot Analysis
Antibodies Clone Sources
c-MET Rabbit polyclonal IBL (Gunma, Japan)
phospho-c-MET
(Y1234/Y1235)
(#3126)
Rabbit polyclonal Cell Signaling Technology
(Danvers, MA)
phospho-ERK
(Tyr202/Tyr204)
(#9101)
Rabbit polyclonal Cell Signaling Technology
(Danvers, MA)
phospho-AKT
(Ser473) (#9271)
Rabbit polyclonal Cell Signaling Technology
(Danvers, MA)
Anti-rabbit IgG
peroxidase
conjugate
Amersham (Arlington
Heights, IL)
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performed using GIM (Genome Imbalance Map) algorithm as
described previously.14
Western Blot Analysis
Western blot analysis was performed as described pre-
viously.6 The luminescence signal was detected and analyzed
with the ChemiDoc XRS image analysis system (Bio-Rad,
Tokyo, Japan).
Cell Proliferation Assay
Cell viability was measured by the Cell Counting Kit-8
assay (Dojindo, Kumamoto, Japan) following the manufac-
turer’s instructions. Cells (4–8  103 cells) were plated in
each well of 96-well microtiter plates. After 24 hours, PHA-
665752 (kindly provided by Dr. J. Christensen, Pfizer) was
added to each well to a final concentration of 10, 3.3, 1, 0.1,
0.01, and 0.001 M. Cells were incubated for additional 4
days at 37°C. The absorbance of each well at 450 nm was
measured with a reference at 630 nm using a Bio-Rad model
680XR microplate reader (Bio-Rad, Hercules, CA). IC50
value was calculated using a software GraphPad Prism 5
(GraphPad Software, Inc., San Diego, CA).
Statistical Analysis
The Mann-Whitney U test was used to evaluate the
correlation between drug sensitivity and the expressions of
MET, phospho-MET, and EMT markers and the correlation
between genetic status and the expressions of EMT markers.
The results were considered significant if the p value was less
than 0.05. All statistical calculations were performed using the
StatView computer program (Abacus Concepts, Berkeley, CA).
RESULTS
Sensitivity of Non-small Cell Lung Cancer Cell
Lines to PHA665752, a MET Tyrosine Kinase
Inhibitor
We examined a panel of 41 non-small cell lung cancer
cell lines to assess their sensitivity to PHA665752 (Figure 1).
We set the levels of sensitivity as “sensitive,” “intermediate,”
and “resistant,” defining them as IC50 1  10
7 M, 1 
107 M  IC50  3.3  10
6 M, and IC50 3.3  10
6 M,
respectively. As a result, 3 cell lines (H1648, EBC1, and
H1993) were deemed to be sensitive, 5 cell lines (A549,
H522, PC14, L27, and H2009) intermediate, and the remain-
ing 33 cell lines resistant. Figure 2 shows a representative
dose-response curve for each group of cell lines.
Figure 1 also shows the genetic statuses of the 41 cell
lines. MET amplification was found in 4 cell lines (H1648,
EBC1, H1993, and L27); MET mutation in 2 cell lines (H596
and H1838); EGFR mutation in 6 cell lines (HCC827,
HCC4006, PC3, PC14, H1650, and H1975); EGFR amplifi-
cation in 3 cell lines (HCC827, H1838, and HCC4006);
HER2 mutation in 1 cell line (H1781); HER2 amplification in
1 cell line (Calu3); and KRAS mutation in 11 cell lines
(A549, H23, H358, H441, H460, H650, H2009, HLC-1,
Lu65, RELF-LC-Ad1, and RELF-LC-Ad2). The MET am-
plification, MET mutation, EGFR mutation, HER2 mutation,
HER2 amplification, and KRAS mutation were all mutually
exclusive, whereas EGFR amplification coexisted with either
EGFR mutation or MET mutation. All the sensitive cell lines
harbored MET amplification, and all four cell lines with MET
amplification showed some sensitivity to PHA665752. This
suggests that MET amplification is an excellent molecular
predictor of susceptibility to the MET inhibitor. However,
Figure 1 also shows that MET amplification was not the sole
determinant of sensitivity to PHA665752, because four of the
five cell lines showing intermediate sensitivity harbored no
MET amplification. It was also of note that H596 and H1838,
the two cell lines harboring MET mutation, were resistant to
PHA665752.
The distribution of PHA665752 sensitivity differed
among KRAS-mutated cell lines. Two of the KRAS-mutated
cell lines (A549 and H2009) showed intermediate sensitivity,
four others (H441, Lu65, RELF-LC-Ad1, and H23) were
resistant but showed some response at 3.3 106 M, and the
remaining five were highly resistant with minimal inhibition
at 3.3  106 M.
We were interested to note that all but one cell lines
harboring genetic abnormalities of the ErbB family showed
some level of resistance to PHA665752. This resistance was
especially strong (IC50 10
5 M) in the cell lines harboring
EGFR amplification, HER2 mutation, and HER2 amplifica-
tion. The one exception, PC14 harbored EGFR mutation, yet
showed an intermediate sensitivity.
Correlation Between Constitutive Activation of
MET and Sensitivity to PHA665752
Next, we examined the expressions of MET and phos-
pho-MET in 41 cell lines by Western blot analysis. MET was
strongly expressed in 16 cell lines (MET/beta-actin 2.0
arbitrary units, red bar in Figure 3A) and activated in 13 cell
lines (p-MET/beta-actin 2.0 arbitrary units, red bar in
Figure 3B). All four cell lines harboring MET amplification
expressed MET and phospho-MET strongly. We confirmed a
good correlation between MET expression and phospho-
MET expression in 41 cell lines by correlation analysis
(Figure 3E, correlation coefficient  0.845). The levels of
MET and phospho-MET expression were significantly higher
FIGURE 2. Dose-response curves of representative cell lines of
each group: H1648 (sensitive), PC14 (intermediate), and LC-
2/ad (resistant). The x axis indicates the log10(concentration of
PHA665752) and the y axis indicates the %cell viability 
(mean absorbance in test wells)/(mean absorbance in control
well)  100.
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FIGURE 3. Expressions of MET and phospho-MET and their relationships with sensitivities to the MET inhibitor. The expres-
sions of MET and phospho-MET were determined by Western blot analysis. The results were corrected for beta-actin and ex-
pressed in arbitrary units. A, Expression of MET in 41 cell lines. The protein expression of MET was consistent with the mRNA
expression of MET determined by oligonucleotide array analysis (not shown). Cell lines were arranged in ascending order of
their IC50 values. MET was strongly expressed in 16 cell lines (MET/beta-actin 2.0, red bars). B, Expression of phospho-MET
in 41 cell lines. Phospho-MET was strongly expressed in 13 cell lines (p-MET/beta-actin 2.0, red bars). C and D, Box and
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in the sensitive and intermediate cell lines than in the resistant
cell lines (MET: p  0.0107, p-MET: p  0.0133, Mann-
Whitney U test) (Figures 3C, D).
Interestingly, the 13 cell lines in which high level of
phospho-MET expression (p-MET/beta-actin 2.0) was
found included not only 4 cell lines harboring MET amplifi-
cations but also 4 cell lines harboring KRAS mutation
(H2009, H441, VMRC-LCD, and RELF-LC-Ad1), 3 cell
lines harboring EGFR mutation (PC14, H1975, and
HCC8227), and 1 cell line with HER2 amplification (Calu3).
These results suggest that sensitivity to the MET inhibitor
correlates with phospho-MET, whereas a high level of phos-
pho-MET expression does not always predict good sensitivity
to the MET inhibitor.
Modest Inhibitory Effect of PHA665752 in
KRAS-Mutated Cell lines with High Levels of
MET or Phospho-MET Expression
Close examination of the responses to PHA665752 at
3.3  106M in Figure 1 revealed that the KRAS-mutated
cell lines behaved somewhat differently from the EGFR-
mutated and HER2-amplified cell lines. The EGFR-mutated
and HER2-amplified cell lines with high level of phospho-
MET (H1975, HCC8227, and Calu-3) showed only minimal
responses (25% inhibition) at 3.3  106 M PHA665752.
In contrast, the KRAS-mutated cell lines with high levels of
MET or phospho-MET (H2009, H441, and RELF-LC-Ad1)
responded modestly at 3.3  106 M PHA665752 (Figures
3F, G). Meanwhile, the KRAS-mutated cell lines with low
levels of MET or phospho-MET were wholly resistant to
PHA665752 (Figures 3F, G). These results suggest that the
MET inhibitor may have a modest inhibitory effect on
KRAS-mutated lung cancer cell lines that strongly express
MET or phospho-MET.
Effects of PHA665752 on MET-Dependent
Signaling
ERK and AKT are important downstream effectors of
EGFR and MET, and the effectiveness of gefitinib is corre-
lated with the inhibition of phospho-ERK and phospho-
AKT.15 To elucidate the correlation between the effectiveness
of PHA665752 and the inhibition of the phosphorylation of
MET, ERK, and AKT, we tested the effect of PHA665752
treatment on ERK and AKT signaling in a subset of cell lines
showing high phosphorylation of MET but variable sensitiv-
ities to the MET inhibitor PHA665752. This subset consisted
of three sensitive cell lines (EBC1, H1993, and H1648), five
resistant cell lines (HCC827, H1975, LC-2/ad, Calu3, and
H441), and one intermediate cell line (H2009). The results
are shown in Figure 4. PHA665752 (1 106 M) effectively
suppressed the constitutive MET phosphorylation in all nine
cell lines tested. Significantly, treatment with this concentra-
tion of PHA665752 also effectively abolished the baseline
phosphorylation of downstream effectors of growth factor
receptors such as ERK and AKT in all three sensitive cell
lines with MET amplification (EBC1, H1993, and H1648). In
contrast, PHA665752 had no effect on the baseline phosphor-
ylation of ERK and AKT in four of the five resistant cell lines
(HCC827, H1975, LC-2/ad, and Calu3); and somewhat par-
adoxically, it activated ERK in Calu3. This indicates that
FIGURE 3. (Continued) whisker plots of MET (C) and phospho-MET (D) expression levels in the sensitive, intermediate, and
resistant groups. E, Correlation between MET and phospho-MET expression in 41 cell lines. The results are shown in a two-
way scatter plot in which the x axis indicates the expression of MET corrected for beta-actin and the y axis indicates the ex-
pression of phospho-MET corrected for beta-actin. Purple, orange, and light blue rhombuses indicate “sensitive,” “intermedi-
ate,” and “resistant” cell lines, respectively. Cell lines harboring MET amplification are surrounded by black circles. F and G,
Expressions of MET (F) and phospho-MET (G) in 11 KRAS-mutated cell lines. Cell lines were arranged in ascending order of
their IC50 values.
FIGURE 4. The effects of PHA665752 on the
phosphorylation levels of MET, ERK, and AKT.
Nine cell lines with high phospho-MET expression
consisted of three sensitive cell lines (EBC1,
H1993, and H1648), five resistant cell lines
(HCC8227, H1975, LC-2/ad, Calu3, and H441),
and one intermediate cell line (H2009). MET de-
phosphorylation was seen in all the cell lines
tested. Dephosphorylation of ERK and AKT were
seen in three of the three MET-amplified cell lines
(EBC1, H1993, and H1648) and one of the two
KRAS-mutant cell lines (“resistant” H441) but not
in the four resistant cell lines (HCC8227, H1975,
LC-2/ad, and Calu3).
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ERK and AKT are activated through an alternative signaling
pathway such as EGFR, HER2, or other growth driver in
these resistant cell lines.
PHA665752 conferred a modest suppressive effect on
ERK and AKT in the two KRAS-mutated cell lines H2009
and H441. This finding was consistent with the PHA665752
sensitivities observed in H441 and H2009 at 3.3 106 M in
Figure 1.
Correlation Between MET and EMT Markers:
E-Cadherin and Vimentin
EMT is associated with resistance to erlotinib.16 It
remains unclear, however, whether a similar association ex-
ists for MET inhibitor as well. To clarify this issue, we
extracted gene expression data of E-cadherin and vimentin
from the oligonucleotide array analysis data. With this data,
we examined the correlation between expressions of MET
and phospho-MET and expressions of E-cadherin and vimen-
tin. E-cadherin gene expression showed modest positive cor-
relations with phospho-MET expression (correlation coeffi-
cient  0.482) and with MET expression (correlation
coefficient  0.361). Vimentin expression showed a modest
negative correlation with MET expression (correlation coef-
ficient  0.365) and a weak negative correlation with
phospho-MET expression (correlation coefficient0.266).
These results suggest that the expression and activation of
MET may be high in cell lines with epithelial phenotype but
lower in cell lines with EMT.
Next, we examined the relationships among1 the ex-
pressions of E-cadherin and vimentin;2 the sensitivities to
MET inhibitor; and3 the genetic statuses of MET, EGFR,
FIGURE 5. Expressions of E-cadherin and vimentin and their relationships with sensitivities to the MET inhibitor. A and B, Box
and whisker plots showing the distribution of E-cadherin (A) and vimentin (B) gene expression levels in the sensitive, interme-
diate, and resistant groups. C and D, Expressions of E-cadherin (C) and vimentin (D), their relationships to the genetic statuses
of MET, EGFR, HER2, and KRAS, and their sensitivities to the MET inhibitor. White bars, brown bars, and black bars indicate
sensitive, intermediate, and resistant cell lines, respectively. Cell lines were arranged according to their genetic abnormalities
as shown in the lower panel. METamp, MET amplification; EGFRmut, EGFR mutation; METmut, MET mutation; HER2amp,
HER2 amplification; HER2mut, HER2 mutation; KRASmut, KRAS mutation.
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HER2, and KRAS. The sensitivity to PHA665752 was not
significantly correlated with the E-cadherin expression (p 
0.3078, Mann-Whitney U test) (Figure 5A) or vimentin ex-
pression (p  0.2298, Mann-Whitney U test) (Figure 5B).
This could be explained by significantly higher expression of
E-cadherin in cell lines with genetic abnormalities of the
ErbB family and MET than the cell lines without the genetic
abnormalities of these kinases (p 0.0046, Mann-Whitney U
test) (Figure 5C). An inverse trend was observed for vimentin
as well (p  0.0762, Mann-Whitney U test) (Figure 5D).
DISCUSSION
In this study, we examined a panel of non-small cell
lung cancer cell lines to identify the genetic statuses of MET,
EGFR, HER2 and KRAS; the levels of MET expression and
activation; and the expressions of EMT markers (E-cadherin
and vimentin). Next, we used our results to determine
whether these parameters were correlated with susceptibility
to the MET inhibitor, PHA665752. We found that MET
amplification was an excellent molecular marker for suscep-
tibility to PHA665752 in lung cancer cell lines as previously
reported.8 However, our analyses also showed that MET
amplification was not the sole determinant of sensitivity to
PHA665752 or of high MET activation. There were several
non-MET–amplified cell lines with intermediate sensitivities
to PHA665752 and/or with high phospho-MET. EGFR mu-
tation and MET amplification have both been reported to
activate MET.17 Our findings are consistent with this report
and suggest that MET activation may depend not only on
MET amplification or EGFR mutation but also on HER2
amplification or KRAS mutation in some cases.
It was interesting to note that the KRAS-mutated cell
lines with high levels of MET or phospho-MET showed
modest responses at 1.0 to 3.3  106 M PHA665752, even
though both were deemed to be either intermediate or
resistant. We also showed that the phosphorylation of ERK
and AKT were inhibited by PHA665752 in KRAS-mutated
cell lines with high phospho-MET. We presume that the
maintenance of optimal cell growth and survival in these
cell lines is dependent not only on the oncogenic mutant
KRAS but also on MET activation. Small pharmacologic
inhibitor is not currently available for the treatment of
KRAS-mutated tumors. Our results support the view that a
subset of KRAS-mutated tumors may be candidates for
molecularly targeted therapy with MET inhibitors, as pre-
viously suggested from the study using mutant KRAS-
induced mouse lung adenocarcinomas.18
Somatic exon 14 deletion of MET has been detected in
resected non-small cell lung cancer.19–21 This mutation seems
to confer ligand-independent MET activation, and tumors
harboring the mutation are potential candidates for anti-MET
therapy.21 In our data, two MET-mutated cell lines (H596 and
H1838) exhibited low-level expressions of MET and phos-
pho-MET and were resistant to PHA665752. Although rela-
tively few MET-mutated cell lines were actually tested, our
results clearly point to the need to further investigate the role
of MET mutation, especially those resulting in exon 14
deletion, in lung cancer.
Our data also revealed a reverse correlation between
MET expression and EMT. E-cadherin expression is reported
to determine the in vitro sensitivity and predicted clinical
activity of erlotinib in lung cancer patients.16 In this study,
however, we found that PHA665752 differs from erlotinib in
that high expression of E-cadherin is not always correlated
with the sensitivity to PHA665752.
In summary, we have shown that MET amplification is
an excellent predictor of sensitivity to PHA665752 in lung
carcinoma cell lines but not the sole predictor. Although less
specific than MET amplification, high levels of MET and
phospho-MET expression will also be useful as surrogate
markers to select for sensitive tumors. High phospho-MET
and the dependence of the AKT and ERK pathways on MET
activation may predict sensitivity to PHA665752, especially
in KRAS-mutated cell lines. Finally, our results will provide
a rational basis for selecting lung cancer patients who may
benefit from MET-targeted therapy.
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